ACADIA Pharmaceuticals Inc. (LON:0A4W)

Market Cap	2.81B
Revenue (ttm)	771.11M
Net Income (ttm)	177.15M
Shares Out	n/a
EPS (ttm)	1.06
PE Ratio	15.86
Forward PE	49.94
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,241
Average Volume	2,167
Open	18.75
Previous Close	18.64
Day's Range	18.62 - 18.97
52-Week Range	14.18 - 26.65
Beta	n/a
RSI	58.25
Earnings Date	May 7, 2025

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin which completed Phase III clinical trial to...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1993
• Employees: 654
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0A4W

Financial Performance

Financial numbers in USD